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Cytokines produced by CD4+ T-helper (Th  )  lymphocytes 
are critical for protective and pathogenic immune 
responses. According to their cytokine production, Th   
cells can be categorised into at least four functionally 
distinct lineages, called Th  1, Th  2, Th  17, and Treg. 
Diﬀ  erentiation of naive Th    cells is induced upon antigen 
recognition in the presence of instructive cytokines, 
resulting in the upregulation of so-called master 
transcription factors – that is, T-bet, GATA-3, retinoic 
acid-related orphan receptor γt (RORγt), or FoxP3 for 
Th  1,  Th  2,  Th   17, or Treg cells, respectively – and imprint-
ing of functionally relevant genes, such as genes encoding 
for cytokines and chemokine receptors [1,2].
Th  17 cells were originally characterised by their co-
expres  sion of IL-17 (also called IL-17A) together with 
IL-17F, TNFα, granulocyte–macrophage colony-stimu-
lat  ing factor, and lymphotactin, but not Th   1 or Th  2  cyto-
kines [3,4]. Over the past several years it has become 
clear that Th  17 cells do not represent a homo  geneous 
lineage. IL-17 can be coexpressed with a variety of other 
cytokines including IL-21, IL-22, IFNγ, IL-10, and IL-4, 
with consequences for the cells’ functionality [1,2,5-7]. 
Moreover, IL-17 is not exclusively produced by CD4+
cells but also by CD8+ T cells, γδ T cells, natural killer T 
cells, natural killer cells, and perhaps also neutro  phils, 
mast cells, and others [2]. Not all IL-17 producers 
therefore are Th   17 cells. One possible current deﬁ  nition 
of Th   17 cells would be CD4+ Th    cells that express IL-17A, 
the IL-23 receptor, and CCR6, and have high levels of 
expression of the transcription factor RORγt in the 
absence of signiﬁ    cant expression of other lineage-speciﬁ  c 
transcription factors and cytokines. In humans, CD161 
expression has been described as a surface marker for 
Th   17 cells [7].
IL-17A and IL-17F are highly homologous (50% amino 
acid identity) and share the same receptor. Yet they 
perform distinct functions. IL-17A seems to be more 
relevant for the development of autoimmunity and 
inﬂ  am  mation than IL-17F, and also plays important roles 
in the host defence against bacterial and fungal 
infections, whereas IL-17F is mainly involved in mucosal 
host defence mechanisms [8].
Th   e main physiological function of IL-17 is the recruit-
ment, activation, and migration of neutrophils. Conse-
quently, IL-17 is critically involved in defence against 
extracellular pathogens, including fungi [9]. Lack of Th  17 
diﬀ  erentiation or function results in increased suscepti-
bility to extracellular bacterial and fungal infections in 
humans [10,11].
Th  17 cells are central for the pathogenesis in many 
murine models of inﬂ   ammatory diseases. Th  ese cells 
contri  bute to inﬂ  ammation through the recruitment of 
neutrophils and the induction of secretion of proinﬂ  am-
matory mediators such as IL-6, IL-8, TNFα, IL-1β, 
CXCL1, CXCL10, and matrix metalloproteinases from 
tissue cells [4,9]. In particular, IL-17 is pathogenetically 
relevant in most murine models of arthritis with the 
notable exception of proteoglycan-induced arthritis, 
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© 2011 BioMed Central Ltdwhich is IFNγ dependent [4,12]. Injection of IL-17 into a 
mouse knee joint induces cartilage degradation, and 
IL-17 overexpression induces bone erosion and cartilage 
degrada  tion [12]. In man, acting synergistically with IL-1 
and TNFα, IL-17 was originally shown to induce massive 
IL-6 production in synovial ﬁ  broblasts [4]. Th  e  frequency 
of IL-17-producing cells in the synovium correlates with 
disease severity in juvenile idiopathic arthritis, 
rheumatoid arthritis, and psoriatic arthritis [13,14]. In 
addition, there is a wealth of data demonstrating the 
presence of IL-17 in inﬂ   ammatory lesions in other 
diseases.
While the prevailing view holds Th   17 cells responsible 
for pathology in most inﬂ  ammatory diseases, recent data 
also support a tissue-protective function of IL-17 in 
models of graft versus host disease, colitis, and bronchial 
hyperreactivity [2]. Whether IL-17-producing Th   cells 
exert pathogenic or protective eﬀ  ects depends partly on 
coexpressed cytokines, tissue-speciﬁ   c factors, and the 
pathogenesis stage. Th   cells that coexpress IL-17 and 
IL-22 together with Th  2 cytokines contribute to the 
patho  genesis of human asthma and a murine model 
thereof [6], whereas IL-17 alone suppresses bronchial 
hypersensitivity in the eﬀ  ector phase of the disease.
In a murine model for multiple sclerosis (experimental 
autoimmune encephalitis), Th   cells that recognise a 
myelin autoantigen and produce IL-17, IL-22, CXCL10, 
CCL2, and CCL5 induce disease upon adoptive transfer 
into recipients. In contrast, IL-17-producing Th   cells 
recognising the same myelin autoantigen, which produce 
IL-17 together with IL-10, IL-22, and CCL20, are unable 
to cause disease and even protect recipient mice from the 
pathogenic eﬀ  ect of the aforementioned IL-17 producers 
[5]. In humans, IL-17-producing RORγt+Foxp3+T cells 
that retain their ability to suppress eﬀ  ector lymphocytes 
have been described [9,15]. It is noteworthy in this 
context that transforming growth factor beta is an impor-
tant instructive signal for the development of both Th  17 
and iTregs. In response to IL-6, the transcription factor 
IRF-4 suppresses FoxP3 expression while increasing 
RORγt expression, resulting in the development of Th  17 
cells rather than iTregs [16].
Th   17 cells can be converted into other Th    subtypes or 
nonclassical Th  17 cells that coexpress other lineage-
deﬁ  ning cytokines [1,2,7,9,15,17]. It has become obvious 
that the expression of cytokines and master transcription 
factors is ﬂ  exible in Th   cells [1,2,9,15,17], breaking the 
dogma of ﬁ  xed Th    lineages. A thorough appreciation of 
the ﬂ  exibility inherent in Th   -cell cytokine production will 
probably halt the currently popular tendency to label 
every Th   cell that produces a particular combination of 
cytokines as a distinct T-cell lineage. For example, Th  17 
cells can be converted into Th  1/Th  17 cells expressing 
both IFNγ and IL-17 by combined IFNγ and IL-12 
signalling. IFNγ is required to upregulate expression of 
the IL-12Rβ2 chain, and IL-12 is required for Th  1 
polarisation. Th  ese  Th  1/Th   17 cells stably coexpress 
RORγt and T-bet [17]. Such ﬂ  exibility is pathogenetically 
relevant. Diabetes induction by adoptive transfer of 
highly puriﬁ  ed  Th  17 cells expressing the diabetogenic 
BDC2.5 T-cell receptor could surprisingly be prevented 
with antibodies against IFNγ but not with anti-IL-17 
antibodies. Isolation and re-analysis of the trans  ferred 
Th  17 cells showed that they had down  regu  lated RORγt 
and IL-17 expression and had upregulated T-bet and 
IFNγ [18]. Jenkins and coworkers demon  strated that 
Th   17 cells elicited in response to Listeria monocytogenes 
declined faster after the infection than did Th   1 cells [19]. 
Th   eir results suggest that Th   17 cells are less likely to give 
rise to long-lived memory Th    cells, although it is not clear 
whether the Th   17 cells have lost their IL-17 expression or 
have died.
In conclusion, given the highly complex mechanisms of 
diﬀ  erentiation, cytokine coexpression, and pathogenic or 
protective eﬀ  ector functions of Th  17 cells, the speciﬁ  c 
modulation of Th  17  eﬀ   ector functions is a major 
therapeutic challenge. Current treatment options for 
autoimmune diseases include the blockade of IL-1, IL-6, 
and IL-23 (p40). Since these cytokines are relevant for the 
induction or maintenance of Th   17 cells, the therapeutic 
eﬃ   cacy may partly be due to reduced IL-17 production. 
Two human  ised antibodies against IL-17A are currently 
in clinical trial for rheumatoid arthritis, psoriasis, and 
uveitis, and the ﬁ  rst results look promising [20,21]. Th  e 
eﬀ  ects of blocking IL-17F alone or together with IL-17A 
or other IL-17 family members in patients are not yet 
known. One can safely assume that much will be learned 
about the relevance of IL-17 family members for human 
diseases once the data from large clinical trials are 
publicly available.
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